Depressive Symptoms
Conditions
Keywords
Cancer, Depression, MBCT, CBT
Brief summary
The purpose of this study is to determine whether mindfulness-based cognitive therapy (MBCT) and cognitive behavioral therapy (CBT) are effective in reducing depressive symptoms in patients after cancer
Detailed description
Cancer patients are prone to develop depressive symptoms, even after curative treatment. Conventional therapies such as cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) are frequently used for reducing these depressive symptoms in patients with medical conditions. However, until now evidence from proper designed randomized controlled trials regarding the effectiveness of both interventions in cancer survivors, is lacking. Therefore, our longitudinal study aims to investigate the effectiveness of CBT and MBCT in reducing depressive symptoms in cancer survivors. In addition, potential moderators and mediators of each intervention will be explored.
Interventions
The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
BEHAVIORALCognitive Behavioral Therapy (CBT)
The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
Sponsors
University of Groningen
Dutch Cancer Society
University Medical Center Groningen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent * Completion of curative cancer treatment (for primary diagnosis of cancer or possible recurrence of cancer) at least one year ago and no longer than five years ago. * Currently no active cancer. * ≥ 18 at the time of diagnosis of cancer and ≤ 75 at inclusion. * Depressive symptoms as assessed by a Patient Health Questionnaire (PHQ-9) score ≥ 10 (indicating presence of at least mild depressive symptoms). * Being able to read, write, and speak Dutch.
Exclusion criteria
* Severe psychiatric co-morbidity (i.e. acute suicidal ideations or behavior, recently experienced psychosis, diagnosis of schizophrenia, bipolar disorder, drug abuse or substance dependence, serious cognitive or neurological problems). * Receiving psychological treatment for depressive symptoms, currently or less than two months prior to study participation. * Unstable antidepressant medication regimen two months prior to inclusion of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in severity of depressive symptoms | pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up | Severity of depressive symptoms will be assessed with the Beck Depression Inventory-II (BDI-II) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in generalized anxiety | pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up | Generalized anxiety is measured by the Generalised Anxiety Disorder Assessment (GAD 7) |
| Change in well-being | pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up | Well-being is measured by the WHO Well-being Index (WHO-5) |
| Change in fear of recurrence | pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up | Fear of recurrence will be measured by Concerns About Recurrence Scale (CARS) |
| Change in fatigue | pre-treatment (baseline) to post-treatment (approximately 3 months after baseline) and 3- and 9-month follow-up | Fatigue is measured by the subsequent scale of the Multidimensional Fatigue Inventory (MFI-20) |
Countries
Netherlands
Contacts
Primary ContactAnnika Tovote, Dr.
Outcome results
None listed